peginterferon alfa-2a HBV
Selected indexed studies
- Chronic Hepatitis B Infection: A Review. (JAMA, 2018) [PMID:29715359]
- Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B. (N Engl J Med, 2024) [PMID:39774313]
- VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study. (Lancet Gastroenterol Hepatol, 2024) [PMID:39389081]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Chronic Hepatitis B Infection: A Review. (2018) pubmed
- Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B. (2024) pubmed
- VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study. (2024) pubmed
- Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B. (2025) pubmed
- Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B. (2018) pubmed
- Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection. (2019) pubmed
- Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. (2005) pubmed
- Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals. (2017) pubmed
- Peginterferon Alfa-2a (40KD) Plus Lamivudine or Entecavir in Children With Immune-Tolerant Chronic Hepatitis B. (2021) pubmed
- Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children With Chronic Hepatitis B: The PEG-B-ACTIVE Study. (2018) pubmed